-
Examination of Different Segments of Health Literacy and Health Awareness Among Pregnant Women
Mar 10, 2025, 14:00 PM -
Impact of Cirrhosis on Health-Related Quality of Life and Activity Among Patients with Metabolic Dysfunction-Associated Steatohepatitis in France, Italy, Germany, and Canada
Mar 10, 2025, 14:00 PM -
Can We Move Beyond a Best Guess? The Feasibility of Transportability Analysis to Estimate the Effect of GLP-1 Inhibitors in the Canadian Population
Mar 10, 2025, 14:00 PM -
Epidemiology and Disease Burden of Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease, and Systemic Inflammation in Northern China: A Retrospective Study of Tianjin Regional Electronic Health Records
Mar 10, 2025, 14:00 PM -
Impact of Using Telehealth in Primary Care on Healthcare Resource Utilization, Costs, and Medication Adherence in Diabetic Patients
Mar 10, 2025, 14:00 PM -
Modeling in R: Tutorial for Beginner Using a Cost-Effectiveness Analysis Made With Microsoft Excel
Mar 10, 2025, 14:00 PM -
Trends in the Prescribing and Dispensing of GLP-1 Anti-Obesity Medications Among U.S. Adults with Cardiovascular Disease and Overweight or Obesity, 2021-2024
Mar 10, 2025, 14:00 PM -
How HTA Should Consider the Global Value of Health Products to Support Public Decision?
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness of Pembrolizumab as First-Line Treatment for Patients with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Unresectable or Metastatic Colorectal Cancer (CRC) from Public Payer Perspective in Brazil
Mar 10, 2025, 14:00 PM -
Estimating US Cancer Prevalence With Community Oncology EHR-Based Datasets via National Benchmarks From SEER and NPCR
Mar 10, 2025, 14:00 PM -
Content Validation of the NEI-VFQ-25 With Patients With Subfoveal and Non-subfoveal Geographic Atrophy: A Qualitative Study
Mar 10, 2025, 14:00 PM -
Utilization and Impact of GLP-1s: Patient-Reported Healthcare Resource Utilization and Costs in Patients With Type 2 Diabetes
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness of Sotagliflozin for Patients With Type 1 Diabetes and Chronic Kidney Disease, With and Without Dynamic Pricing
Mar 10, 2025, 14:00 PM -
Real-world Impact of the United States Preventive Services Task Force (USPSTF) Guidelines on HIV-1 Pre-Exposure Prophylaxis (PrEP) Ancillary Service Cost Sharing: Segmented Change Pre- and Post-Milestone USPSTF Timepoints
Mar 10, 2025, 14:00 PM -
Time-Driven Activity-Based Costing in Healthcare: Should We Adjust for Inflation or Reapply the Method?
Mar 10, 2025, 14:00 PM -
Understanding the Caregiver Experience Through an Exploration of the Literature
Mar 10, 2025, 14:00 PM -
Economic Burden of Prader-Willi Syndrome Among Pediatric Patients in the United States
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness Analysis of HIV Prevention and Treatment Portfolios in US Prison Settings
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness Analysis of Adjuvant Pembrolizumab Versus Standard-of-Care (SOC) Immunotherapies (High-Dose interferon Alfa 2-b or Ipilimumab) in High-Risk Resected Melanoma in United States (US)
Mar 10, 2025, 14:00 PM -
Healthcare Resource Utilization of Adult Patients with Obesity Before vs. After GLP-1 Treatment in the United States Elective Outpatient Setting
Mar 10, 2025, 14:00 PM
